Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | PHASE3 | ACTIVE NOT_RECRUITING | 509 | — | — | May 31, 2023 | Mar 26, 2028 | Jan 5, 2026 | 223 | United States, Argentina +29 |
| NCT06745323 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | PHASE2 | ACTIVE NOT_RECRUITING | 252 | — | — | Feb 26, 2025 | Feb 9, 2029 | Mar 3, 2026 | 78 | United States, Argentina +14 |
OS was defined as time from randomization until death from any cause. Median overall survival was estimated using Kaplan-Meier method. 95% confidence intervals (CIs) were calculated using the Brookmeyer and Crowley method.
| Arm | Type | Description |
|---|---|---|
| Tarlatamab | EXPERIMENTAL | Participants will receive tarlatamab as an intravenous (IV) infusion. |
| Standard of Care | ACTIVE_COMPARATOR | Participants will receive treatment per local standard of care (SOC). |
| Treatment Arm A: Dose 1 Tarlatamab | EXPERIMENTAL | Participants will receive dose 1 of Tarlatamab by intravenous (IV) infusion during the treatment period. |
| Treatment Arm B: Dose 2 Tarlatamab | EXPERIMENTAL | Participants will receive dose 2 of Tarlatamab by IV infusion during the treatment period. |
| Treatment Arm C: Dose 3 Tarlatamab | EXPERIMENTAL | Participants will receive dose 3 of Tarlatamab by IV infusion during the treatment period. |
| Name | Type | Description |
|---|---|---|
| Tarlatamab | DRUG | Tarlatamab will be administered as an IV infusion. |
| Lurbinectedin | DRUG | Lurbinectedin will be administered per local SOC. |
| Topotecan | DRUG | Topotecan will be administered per local SOC. |
| Amrubicin | DRUG | Amrubicin will be administered per local SOC. |
Inclusion Criteria: * Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent. * Histologically or cytologically confirmed SCLC wit...